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Abstract
Background: This study aims to compare the effectiveness and safety of topical versus intravenous tranexamic acid
(TXA) in reducing blood loss in primary total knee arthroplasty (TKA).
Methods: PubMed, Embase, the Cochrane Library, Web of Science, Chinese Biomedicine Literature (CBM), Wanfang
Database and China National Knowledge Infrastructure (CNKI), and Google Scholar were searched for randomized
controlled studies (RCTs) that compared topical versus intravenous TXA in terms of reducing blood loss during TKA
from their inception to September 2015. This systematic review and meta-analysis was performed according to
PRISMA criteria.
Results: Twelve studies reporting 12 RCTs comprising 1130 patients were included. Compared with the intravenous
administration of TXA, the topical administration of TXA showed no significant differences in total blood loss (MD 2.08,
95% CI −68.43 to 72.60, P = 0.95), blood loss in drainage (MD 18.49, 95% CI −40.01 to 76.98, P = 0.54), hidden blood loss
(MD 4.75, 95% CI −337.94 to 347.44, P = 0.99), need for transfusion (RR = 0.92, 95% CI 0.67~1.25, P = 0.58), hemoglobin
(Hb) decline (MD −0.42, 95% CI −0.89 to 0.05, P = 0.08), and DVT occurrence (RR = 1.17, 95% CI 0.55~2.50, P = 0.68).
Conclusions: Compared with intravenous administration TXA, topical administration TXA exhibits comparable
effectiveness and safety in terms of reducing blood loss during TKA. Due to the poor quality of the included studies,
more high-quality RCTs are needed to identify the optimal method and dose of TXA after TKA.
Keywords: Tranexamic acid, Total knee arthroplasty, Meta-analysis
Background
Total knee arthroplasty (TKA) is an effective treatment
that helps to relieve severe pain and handicap induced
by knee joint disease. However, TKA may cause
significant perioperative blood loss ranging from 800 to
1800 mL, and 10 to 38% of patients need allogeneic
blood transfusion [1–5]. Blood loss and subsequent
blood transfusion can increase cost, and many
complications, such as infection with HIV or other in-
fectious diseases, fluid overload, and graft-versus-host
disease can occur [6].
Many methods have been used to decrease blood loss
during TKA, including the use of tourniquet, fibrin seal-
ant, and tranexamic acid (TXA) [7–9]. The hemostasis
effect of tourniquet in TKA is controversial. Wang et al.
[10] revealed that total and intra-operative blood losses
were reduced only with long-duration tourniquet use,
while Zhang et al. [11] found that tourniquet release at
the end of the TKA will activate local fibrinolysis and
might increase blood loss. Auguilera et al. [12] reported
* Correspondence: shandongjb@qq.com
2Hebei University, Yuhua Dong Road, 342, Yuhua District, Baoding, Hebei
Province 071000, China
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Chen et al. Journal of Orthopaedic Surgery and Research  (2017) 12:11 
DOI 10.1186/s13018-017-0512-4
that TXA can be more effective than fibrin sealant in re-
ducing postoperative bleeding and transfusion require-
ment and that fibrin sealant use was not superior to
routine hemostasis.
The use of TXA in primary TKA is today widely
accepted, and several studies and meta-analyses have
confirmed the efficacy of TXA at decreasing blood loss
without increasing complications and costs [9, 13, 14].
Several clinical trials have identified that intravenous
(IV) TXA is effective in reducing perioperative blood
loss and the need for subsequent blood transfusions in
TKA [15–17]. However, deep venous thrombosis (DVT)
after the systemic administration of TXA is still a serious
and fatal complication [18]. Therefore, many researchers
have focused on the topical application of TXA via drain
tube or intra-articular administration, and the topical
application of TXA is considered an alternative effective
route that entails less risk than IV after TKA [19, 20]. A
previous meta-analysis has been published that only in-
cluded five RCTs and one non-RCT [21]. Nevertheless,
the comparative efficacy and safety of topical versus
intravenous TXA often differs between studies. Thus, we
performed a meta-analysis to compare the effectiveness
and safety of topical versus intravenous TXA after TKA.
Methods
Search strategy
The following electronic databases were searched:
PubMed, Embase, the Cochrane Library, Web of Science,
Chinese Biomedicine Literature (CBM), Wanfang Data-
base and China National Knowledge Infrastructure
(CNKI), and Google Scholar were searched by two re-
viewers. Relevant studies comparing the topical adminis-
tration of TXA and intravenous TXA for the management
of blood loss during TKA were identified by two re-
viewers; the search was performed in August 2015. The
keywords and Medical Subject heading (MeSH) terms
used for the search were the following: “TXA,” “tranex-
amic acid” “total knee arthroplasty,” “total knee replace-
ment”, “TKA”, “TKR”, and “Arthroplasty, Replacement,
Knee”[Mesh]; the terms were connected by the Boolean
operators AND or OR. The search string used in our re-
search is presented in appendix A. Additionally, the refer-
ence lists of all identified full-text articles were reviewed
to identify any initially omitted studies. There were no re-
strictions regarding language. Since this is a meta-analysis,
no ethics committee or institutional review board ap-
proval was required.
Eligibility criteria and study quality
Study selection was performed according to the follow-
ing inclusion criteria: (1) studies of patients undergoing
primary TKA intervention; (2) with topical administra-
tion TXA and intravenous TXA as therapy to control
blood loss; (3) studies assessing primary outcomes such
as total blood loss, blood loss in drainage, hidden blood
loss, need for transfusion, hemoglobin decline, and the
rate of complications (DVT); and (4) studies designed as
randomized controlled trials (RCTs). All the studies were
required to be clinical trials. Trials on cadavers or artifi-
cial models were excluded. Letters, comments, editorials,
and practice guidelines were also excluded.
According to the Cochrane Handbook for Systematic
Reviews of Interventions (version 5.1.0) [22], Review
Manager, version 5.3 (The Nordic Cochrane Centre, The
Cochrane Collaboration, Copenhagen, 2014) was used to
describe the quality assessment.
Data extraction
Two reviewers independently extracted and recorded
following data in a spreadsheet: (1) patient demographic
data, author’s name, publication date, sample size, loca-
tion of study, ratio of male and female subjects, the dose
and method of TXA application (topical or intravenous),
and whether TKA was unilateral or bilateral; (2) the
method of anesthesia; and (3) total blood loss, blood loss
in drainage, hidden blood loss, need for transfusion,
hemoglobin decline and rate of complications (deep ven-
ous thrombosis (DVT)). If the data were presented as
figures, the software “Getdata Graph Digitizer” was used
to extract the data for meta-analysis.
Outcome measures and statistical analysis
The main parameters studied were total blood loss,
blood loss in drainage, hidden blood loss, need for trans-
fusion, hemoglobin decline, and rate of complications
(DVT). Hidden blood loss (mL) was calculated as total
blood loss minus blood loss collected from drains. The
results are presented as the mean differences (MDs) with
95% confidence interval (CI) for continuous outcomes
such as total blood loss and blood loss in drainage.
Binary outcomes, such as the need for transfusion and
the occurrence of DVT were presented as relative risk
(RR) values with 95% CI. Statistical significance was set
at P < 0.05. To summarize findings across the trials, the
software RevMan 5.3 (The Cochrane Collaboration,
Oxford, UK) was used to conduct the meta-analysis.
Statistical heterogeneity was tested using the chi-squared
test and the I2 statistic. Chi-squared test results with P >
0.1 were considered suggestive of statistical heterogen-
eity. An I2 statistic greater than 50% was considered to
indicate substantial heterogeneity [23]. A fixed effect
model was adopted if the I2 statistic value was less than
50%. If the I2 statistic value was greater than 50%, a sen-
sitivity analysis was performed using Stata 12.0 (Stata
Corp., College Station, TX, USA) to explore the effect of
an individual study.
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Results
Search result and quality assessment
The initial search yielded 385 potentially relevant stud-
ies; of these, no duplicate was found using Endnote
Software. Based on the inclusion criteria, 374 studies
were excluded after reading the titles and abstracts.
Finally, 12 clinical trials involving 1130 patients were in-
cluded in the meta-analysis [24–36]. The process for
selecting the included studies is presented in Fig. 1. One
study included four IV groups [30], and one report in-
cluded two topical groups that differed in the dose and
timing administration of TXA [32]. Differently dosed
TXA groups were included in this meta-analysis. The
characteristics of the included studies are shown in
Table 1, and the doses and methods used to apply TXA
are summarized in Table 2. In the included studies, 1130
Fig. 1 Flow diagram for the included studies














Patel JN 2014 [31] 47/42 42/64.9 23/66 OA USA ns Con-TKA Yes 4.6
Maniar RN 2012 [30] 40/160 67.4/67.45 42/158 OA India Cemented CAS-TKA Yes 3
Seo JG 2013 [33] 50/50 67.5/66.8 11/89 OA Korea Cemented CAS-TKA Yes 2
Sarzaeem MM 2014 [32] 100/50 67.8/66.9 20/130 OA Iran Cemented Con-TKA Yes –
Soni A 2014 [34] 40/40 69.45/69.05 36/44 OA India Cemented Con-TKA Yes 1.5
Tang Lian 2014 [29] 30/30 66.5/67.1 20/40 OA China ns Con-TKA Yes –
Han WF 2014 [26] 50/50 ns 20/80 OA + RA China Cemented Con-TKA Yes 3 months
Aguilera X 2015 [24] 50/50 72.53/72.49 70/30 OA + RA + DKD Spain Cemented Con-TKA Yes 2
Digas G 2015 [25] 30/30 70/71 51/49 OA Germany Cemented Con-TKA Yes 25 days
Jiang Hua 2015 [28] 33/40 ns 54/19 DKD China ns Con-TKA Yes 7 days
Hou ZY 2015 [36] 20/20 67.36/67.02 OA + RA China Uncemented Con-TKA Yes 14 days
NS not stated, T topical group, I intravenous group, OA osteoarthritis, RA rheumatoid arthritis, DKD degenerative knee disorders, Con-TKA conventional total knee
arthroplasty, CAS-TKA computer-assisted total knee arthroplasty
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TKAs were performed, and the numbers of topical TXA
and intravenous TXA were 529 and 601, respectively.
Eight articles were in English, and four studies were in
Chinese; all were published between 2013 and 2015. All
participants in the 12 studies were elderly patients aged
between 42 and 72.5 years who were planning to undergo
TKA. Tourniquet was applied in all of the included stud-
ies, and the pressure of the tourniquet ranged from 100 to
350 mmHg. Detailed information regarding the risk of
bias in the included studies is shown in Figs. 2 and 3.
Meta-analysis results
Blood loss (total blood loss, blood loss in drainage, and
hidden blood loss)
Five trials [12, 25, 27, 29, 30] reported data on topical ver-
sus intravenous administration for reducing total blood
Table 2 Dose and method for topical and intravenous administration of TXA
Author/s Intervention Methods of administration the tranexamic acid Transfusion
criteria
Thromboprophylaxis
Topical IV Topical IV
Gomez-Barrenna
2014 [27]
3 g/100 mL 15 mg/kg.
2 doses
One dose irrigated before
joint closure, and the
other half was administered
intra-articularly after skin
closure
Fifteen to 20 min
before tourniquet
release and 100 mL 3 h
Hb <80 g/L NS




2 min TA before tourniquet
release, with drain















5 min TXA before tourniquet
release, clamp drain 2 h
then fully open
One dose as IO
Two doses as IOPO
Two doses as POIO
Three doses at POIOPO
Hb b 8.5 g/dL
Hb b 10.0 g/dL
+ symptom
LMWH








Hb b 8.0 g/dL











1.5 g TXA: IXA injected through
the drain after wound closure
3 g TXA: 5 min TXA before




Hb b 7.0 g/dL









5 min TXA before tourniquet




Hb b 8.0 g/dl LMWH
Tang Lian
2014 [29]







Hb <90 g/L LMWH
Han Wenfeng
2014 [26]
1 g/50 mL 15 mg/kg,
maximum
1.2 g
Spray the TXA before suction




Hb <70 g/L LMWH
Aguilera X
2015 [24]
1 g/10 mL 1 g *
2 doses
The TXA was applied by syringe
spray and drain was kept closed
during the first hour and removed
24 h after surgery












2 g 15 mg/kg
1 dose









2 g/100 mL 10 mg/kg
1 dose






500 mg/10 mL 10 mg/kg
1 dose
Intra-articular Before insert the
prosthesis
Hb <70 g/L Rivaroxaban
NS not stated, Hb hemoglobin, LMWH low molecular weight heparin, IO intra-operative, IOPO intra-operative and postoperative, POIO postoperative and intra-
operative, POIOPO postoperative, intra-operative, and postoperative, TXA tranexamic acid
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loss after TKA. Statistical heterogeneity was found (χ2 =
41.56, I2 = 83%, P < 0.00001, Fig. 4), and a random-effects
model was performed. Topical administration of TXA
showed no significant difference (MD2.08, 95% CI −68.43
to 72.60, P = 0.95, Fig. 4) in reducing total blood loss com-
pared with intravenous TXA. A total of 10 studies [24–28,
32–34, 36] compared topical versus intravenous TXA in
terms of reducing blood loss in drainage. Statistical het-
erogeneity (χ2 = 864.26, I2 = 98%, P < 0.00001, Fig. 4)
occurred, and a random-effects model was performed.
Similarly, the topical application of TXA did not sig-
nificantly decreased the blood loss in drainage after
TKA (MD18.49, 95% CI −40.01 to 76.98, P = 0.54,
Fig. 4) compared with intravenous administration. For
hidden blood loss, statistical heterogeneity (χ2 = 39.60,
I2 = 95%, P < 0.00001, Fig. 4) was found, and a
random-effects model was performed. There was no
significant difference between the topical and
intravenous groups (MD 4.75, 95% CI −337.94 to
347.44, P = 0.99, Fig. 4).
Need for transfusion
Fifteen studies [24–27, 29–34, 36] mentioned a need
for transfusion in 1206 enrolled knees. No significant
heterogeneity (χ2 = 13.20, I2 = 2%, P = 0.43) was found.
This paper uses a fixed-effects model, and no signifi-
cant difference was found between topical TXA
groups and intravenous TXA groups regarding the
need for transfusion (RR = 0.92, 95% CI 0.67~1.25, P =
0.58) (Fig. 5).
Hemoglobin decline
No significant difference was found between the IV
TXA with topical TXA groups (MD-0.42, 95% CI
−0.89 to 0.05, P = 0.08, Fig. 6). Statistical heterogen-
eity (χ2 = 107.72, I2 = 94%, P < 0.00001, Fig. 6) exists,
and a random-effects model was performed. To elim-
inate heterogeneity, a subgroup analysis was carried
out for hemoglobin decline (Table 3).
Thromboembolic complications
Fourteen studies provided data about the rate of
thromboembolic complications; the results of the
meta-analysis indicate that the rate of thrombo-
embolic complications for the intravenous group is
1.93% and that for the topical group is 1.58%; no sig-
nificant difference was found between the two groups
(RR = 1.17, 95% CI 0.55~2.50, P = 0.68, Fig. 7). No sta-
tistically heterogeneity (χ2 = 5.72, I2 = 0%, P = 0.68,
Fig. 7) was found; therefore, a fixed-effects model was
performed.
Other outcomes
Since the sample of other identified outcomes was
not large enough for meta-analysis, we performed a
descriptive analysis. For instance, Seo [33] found no
significant difference between the range of motion be-
tween the two groups; the average ranges of motion
(ROMs) at 2 months were 2.6°–123.3° and 2.5°–120.4°
in the intravenous and intra-articular groups, and no
significant difference was found in the intergroup
Fig. 2 Summary of the risk of bias in each study
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analysis. The ranges of motion 1 month postopera-
tively were 104° ± 10° (95% CI, 101° to 108°) in the
topical group and 105° ± 11 (95% CI, 101° to 109°) in
the intravenous group (P = 0.612) [27]. There were 0
and 1 cases of atrial fibrillation in the topical TXA
and IV TXA groups, respectively. Saezaeem [32] re-
ported just one postoperative complication in the
injected TXA group; this involved a patient with skin
necrosis and more joint swelling than that seen for
the intravenous group. One case of acute kidney
Fig. 3 Graph of the risk of bias for the included studies
Fig. 4 Forest plots comparing topical versus intravenous TXA administration regarding the need for transfusion. A Mantel-Haenszel fixed-effects
model was used. Mean differences are shown with 95% CI
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injury was found in each of the topical and IV TXA
groups [31].
Sensitivity analysis
A sensitivity analysis of blood loss in drainage was con-
ducted, and the results indicated that none of the studies
affected the stability of the final results (Fig. 8).
Discussion
The results of the current meta-analysis indicate that
there were no significant differences in total blood loss,
blood loss in drainage, hidden blood loss, need for trans-
fusion, and minimal hemoglobin decline between topical
TXA and IV TXA groups in primary TKA. Moreover,
no significant difference was found in the rate of DVT
between the two groups. Moreover, no adverse effects
were reported in the included studies.
Patients undergoing TKA may suffer from large blood
loss due to the large area of osteotomy and enhanced
local fibrinolysis after tourniquet release [37]. Total
blood loss can be 300 mL higher than that occurring
with no tourniquet use. Thus, the topical administration
of TXA can reduce postoperative blood loss when
combined with the use of a drainage clamp. Further-
more, Jawhar et al. [38] reported that tourniquet use can
induce ischemia during TKA and can result in higher
proteolytic activity within vastus medialis cells, which
may increase hidden blood loss. Compared with intra-
venous TXA administration, intra-articular TXA admin-
istration can be rapidly absorbed, maintaining a
biological half-life of approximately 3 h within the joint
fluid; this may be the reason why patients benefit from
topical TXA administration [39]. TXA is an antifibrino-
lytic agent that activates plasminogen and stops bleeding
without increasing plasma fibrin levels [40]. Several
studies and meta-analyses have identified TXA as an ef-
ficacious and safe way to reduce blood loss in patients
who undergo TKA [41–43], and numerous studies have
focused on the efficacy of topical TXA administration in
reaching a maximum hemostatic effect [44–46]. How-
ever, the most effective TXA regimen in primary TKA
remains uncertain. A meta-analysis on outcomes was
previously conducted to explore the difference between
the two groups [21]. However, in their study, five RCTs
and one prospective cohort study were included; more-
over, they did not compare hidden blood loss between
Fig. 5 Forest plots comparing topical versus intravenous TXA for the need for total blood loss, blood loss in drainage, and hidden blood loss. An
inverse-variance random-effects model was used. Mean differences are shown with 95% CI
Fig. 6 Forest plots comparing topical and intravenous TXA administration in terms of Hb decline. An inverse-variance random-effects model was
used. Mean differences are shown with 95% CI
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the two groups. The current meta-analysis included
twelve studies and did compare hidden blood loss, which
comprises a large proportion of total blood loss.
With regard to the need for transfusion, no signifi-
cant difference was found between the two groups
(RR = 0.92, 95% CI 0.67~1.25, P = 0.58); the dose of
topical administration ranged from 0.5 to 3 g, and
the dose of intravenous TXA administration ranged
from 10 to 15 mg/kg. Three studies reported hidden
blood loss for the two groups, and Aguilera [24]
favors the use of topical administration to reduce hid-
den blood loss after TKA, whereas Hou and col-
leagues [47] found no difference between topical and
intravenous administration. In this meta-analysis, no
significant difference between topical and IV TXA ad-
ministration was found. Our sensitivity analysis
showed that the study of Sarzaeem [32] significantly
affected the heterogeneity results. After carefully
reviewing the study, the main difference between this
study and the other studies is that TXA was adminis-
tered by irrigating with 3 g of TXA and injecting with
1.5 g TXA. In addition, doses of topically adminis-
tered TXA ranging from 0.5 g [48] to 3 g [27, 30, 34,
44, 49] have all proven effective and safe. Regarding
blood loss in drainage, a large degree of heterogeneity
was found between the two groups, and the sensitivity
analysis showed that the inclusion of Sarzaeem’s study
influences the final conclusion. After carefully reading
the article, the topical administration of TXA was ap-
plied by irrigation.
DVT and subsequent PE are fatal complications after
TKA, and it has been reported that 0.1–2% of patients
will suffer from pulmonary embolism following TKA
[50]. Theoretically, intravenous TXA administration may
increase the risk of thrombosis since it is a synthetic
antifibrinolytic agent that can prevent plasminogen acti-
vation, and fibrinolysis is delayed [51]. However, it has
been ascertained that TXA does not inhibit fibrinolytic
activity in the vein wall, and its effect on disrupted endo-
thelium remains unknown [52]. The results of the
current meta-analysis indicate that both topical and
intravenous administration TXA are safe when used to
reduce blood loss during TKA. The frequencies of DVT
after intravenous and topical TXA administration are
11/571 and 9/568, respectively (RR = 1.17, 95%CI
0.55~2.50, P = 0.68). The reasons for this may be as fol-
lows: (1) the doses used during intravenous and topical
administrations are appropriate and do not exceed the
optimal dose; therefore, the fibrinolytic system will not
be suppressed. (2) Most studies only evaluated symp-
tomatic DVT and PE, and this will have affected the final
conclusion.
This meta-analysis has the following limitations: (1)
Only twelve studies were included, and the sample sizes
used in each study were insufficient, which will affect
the conclusions. (2) The studies administered TXA at
different doses and using different methods, causing
large heterogeneity. (3) The duration of follow-up in
Table 3 Subgroup analysis for the hemoglobin drop
Outcome or subgroup Studies Effect estimate
χ2 I2(%) MD 95% CI P value
Non-computer
navigated TKR
4 190.77 98 0.31 −1.26,1.89 0.7
High score RCT 3 193.26 97 0.11 −0.89,1.11 0.83
Fig. 7 Forest plots comparing topical and intravenous TXA administration in terms of the occurrence of DVT. A Mantel-Haenszel fixed-effects
model was used. Relative risk values are shown with 95% CI
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some studies was short; therefore, long-term follow-up
is needed to measure the occurrence of DVT and PE.
Conclusions
In conclusion, this meta-analysis indicated that topical TXA
administration exhibits comparable efficacy and safety to
those of intravenous TXA, and both methods can decrease
the need for transfusion, total blood loss, blood loss in
drainage, and hidden blood loss without increasing the oc-
currence of DVT. Due to the poor quality of the included
studies, more high-quality RCTs are needed to identify the
optimal method and dose of TXA after TKA.
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